Inventor

DIMITER S. DIMITROV

Inventor

Overview

19→

Patents

2022–2026

Patent span

Human necessities

Primary field (CPC A)

Patents· 19 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides27%

A61KPreparations for medical, dental or toiletry purposes25%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%

C12NMicroorganisms or enzymes13%

G01NInvestigating or analysing materials by determining their chemical or physical properties8%

C12YEnzymes1%

PatentTitleYear

12,540,179Compositions and methods for treating cancer with anti-ROR1 immunotherapy2026 12,453,780Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use2025 12,391,958Compositions and methods for treating cancer with anti-CD38 immunotherapy2025 12,037,403Compositions and methods for treating cancer with anti-CD123 immunotherapy2024 12,037,404Human monoclonal antibodies against EphA4 and their use2024 12,018,077Methods of treatments using antigen-binding proteins targeting CD562024 12,012,455Human monoclonal antibodies specific for FLT3 and uses thereof2024 11,970,528Compositions and methods for treating cancer with anti-mesothelin immunotherapy2024 11,939,377Affinity matured CD22-specific monoclonal antibody and uses thereof2024 11,878,052Compositions and methods for treating cancer with anti-CD22 immunotherapy2024 11,851,498Anti-CD276 antibodies (B7H3)2023 11,807,682M971 chimeric antigen receptors2023 11,708,408Compositions and methods for treating cancer with anti-CD19 immunotherapy2023 11,702,472Method of reducing mesothelin-expressing tumor burden by administration of T cells comprising mesothelin-targeted chimeric antigen receptors2023 11,512,138Anti-CD276 polypeptides, proteins, and chimeric antigen receptors2022 11,464,801Compositions and methods for treating cancer with anti-CD33 immunotherapy2022 11,453,719Compositions and methods for treating cancer with anti-ROR1 immunotherapy2022 11,389,480Human monoclonal antibody targeting TNFR2 for cancer immunotherapy2022 11,236,171Human monoclonal antibodies specific for FLT3 and uses thereof2022

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2022–2026Patents assigned to US HEALTH (17)· patent assignee history

2022–2026Patents assigned to LENTIGEN TECH INC (8)· patent assignee history

2022–2023Patents assigned to BIOMED VALLEY DISCOVERIES INC (2)· patent assignee history

2022–2026Based in US· patent location history

2023–2024Patents assigned to MEMORIAL SLOAN KETTERING CANCER CENTER (2)· patent assignee history

2024Patents assigned to LENTIGENTECHNOLOGY INC (1)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
US HEALTH	17	2022–2026
LENTIGEN TECH INC	8	2022–2026
BIOMED VALLEY DISCOVERIES INC	2	2022–2023
MEMORIAL SLOAN KETTERING CANCER CENTER	2	2023–2024
LENTIGENTECHNOLOGY INC	1	2024

Locations

Location	Patents	Span
US	19	2022–2026